Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
The inspection was successfully completed
the inspection conducted from January 27 to January 31, 2025
Observations are largely around improvement of procedures and practices
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
The Alathur facility specializes in the production of Cephalosporin antibiotics
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Subscribe To Our Newsletter & Stay Updated